Navigation Links
Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
Date:4/24/2013

RICHMOND, Calif., April 24, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier , Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 12:50 pm ET on Wednesday, May 1, 2013, at the 12th Annual Needham Healthcare Conference which will be held in New York.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

 


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
2. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
3. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
4. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
5. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
7. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
8. Sangamo BioSciences Reports First Quarter 2012 Financial Results
9. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
10. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2020)... ... 2020 , ... The Security Industry Association (SIA) and SecureIDNews ... the Women in Biometrics Awards – a globally recognized program co-founded by ... and the SIA Women in Security Forum . The honorees will be recognized ...
(Date:5/21/2020)... , ... May 19, 2020 , ... Experienced periodontist in ... get dental implants and bone grafting through PIEZOSURGERY® technology. PIEZOSURGERY uses ultrasonic ... often used to prepare a patient for dental implants, especially when the implants need ...
(Date:5/15/2020)... ... May 14, 2020 , ... ... human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, ... streamlined and multi-format collection of hMSC-derived extracellular vesicles (EVs). RoosterCollect™-EV-CC is the ...
(Date:5/15/2020)... ... May 15, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... as Executive Chairman. Mr. Ganz will continue to lead Sentien’s Board of Directors, ... closely with CEO Brian Miller and Sentien’s management team. , Mr. Ganz ...
Breaking Biology Technology:
(Date:5/1/2020)... ... April 30, 2020 , ... ... diseases, announced today that it had been awarded a contract from the Biomedical ... Secretary for Preparedness and Response at the U.S. Department of Health and Human ...
(Date:4/28/2020)... FT. LAUDERDALE, Fla. (PRWEB) , ... April 27, ... ... official launch. The first-of-its-kind category-defining service was started by three teenagers with an ... a change in the world during the time of great need and suffering, ...
(Date:4/22/2020)... ... April 21, 2020 , ... Captis Biotechnology, ... capital firm that provides patent development support for early stage startups. The investment ... such as ovarian cancer and precancerous pancreatic lesions with simple, accurate and practical ...
Breaking Biology News(10 mins):